苯丙酸諾龍

苯丙酸諾龍
臨床資料
商品名（英語：Drug nomenclature）	Durabolin, others
其他名稱	• NPP; • Nandrolone phenpropionate; • 19-Nortestosterone phenylpropionate; • Nandrolone hydrocinnamate; • 19-Nortestosterone 17β-phenylpropionate; • NSC-23162
懷孕分級	澳: D ; ;
給藥途徑	Intramuscular injection
藥物類別（英語：Drug class）	Androgen; Anabolic steroid; Androgen ester; Progestogen
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：Schedule IV; 英：Class C; 美：附表III;
藥物動力學數據
生物利用度	• Oral: 0.3–2.9% (pigs); • Intramuscular: high
藥物代謝	Blood (hydrolysis), liver (reduction)
代謝產物	• Nandrolone; • 5α-Dihydronandrolone; • 19-Norandrosterone; • 19-Noretiocholanolone; • Conjugates
生物半衰期	• Intramuscular: 2.7 days; • Nandrolone: <4.3 hours
作用時間	• Intramuscular: 5–7 days
排泄途徑	Urine
識別資訊
	IUPAC命名法 [(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] 3-phenylpropanoate; ;
CAS號	434-22-0
PubChem CID	229455;
ChemSpider	199761;
UNII	KF7Z9K2T3W;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID2023353 ;
ECHA InfoCard	100.000.502
化學資訊
化學式	C27H34O3
摩爾質量	406.57 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4=CC=CC=C4)CCC5=CC(=O)CC[C@H]35;
	InChI InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1; Key:UBWXUGDQUBIEIZ-QNTYDACNSA-N;

苯丙酸諾龍（英語：Nandrolone phenylpropionate或 Nandrolone hydrocinnamic，縮寫NPP，商品名為Durabolin）是一種雄激素同化類固醇（AAS）藥物，主要用於治療乳腺癌和骨質疏鬆症女性^[8]^[9]^[10]^[11]^[3]，通過每周一次的肌肉注射進行^[3]。這類藥物過去曾廣泛應用，但現已逐漸停用^[3]^[11]。

參考文獻

^ McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.
^ Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-17]. ISBN 978-0-7817-1750-2. （原始內容存檔於2020-05-17）.
^ ^3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 460–467,193–194. ISBN 978-0-9828280-1-4.
^ ^4.0 ^4.1 Victor A. Rogozkin. Metabolism of Anabolic-Androgenic Steroids. CRC Press. 14 June 1991: 108–. ISBN 978-0-8493-6415-0.
^ ^5.0 ^5.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.
^ ^6.0 ^6.1 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.
^ ^7.0 ^7.1 ^7.2 存档副本 (PDF). [2019-02-17]. （原始內容 (PDF)存檔於2010-12-18）.
^ J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.
^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–717. ISBN 978-3-88763-075-1.
^ I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. ISBN 978-94-011-4439-1.
^ ^11.0 ^11.1 存档副本. [2019-02-17]. （原始內容存檔於2019-08-28）.

[pmid10435281-1] McEvoy JD, McVeigh CE, McCaughey WJ. Residues of nortestosterone esters at injection sites. Part 1. Oral bioavailability. Analyst. 1998, 123 (12): 2475–8. PMID 10435281. doi:10.1039/a804919j.

[Becker2001-2] Kenneth L. Becker. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1185– [2019-02-17]. ISBN 978-0-7817-1750-2. （原始內容存檔於2020-05-17）.

[Llewellyn2011-3] 3.0 ^3.1 ^3.2 ^3.3 ^3.4 ^3.5 William Llewellyn. Anabolics. Molecular Nutrition Llc. 2011: 460–467,193–194. ISBN 978-0-9828280-1-4.

[Rogozkin1991-4] 4.0 ^4.1 Victor A. Rogozkin. Metabolism of Anabolic-Androgenic Steroids. CRC Press. 14 June 1991: 108–. ISBN 978-0-8493-6415-0.

[Thomas2012-5] 5.0 ^5.1 John A. Thomas. Drugs, Athletes, and Physical Performance. Springer Science & Business Media. 6 December 2012: 27–29. ISBN 978-1-4684-5499-4.

[pmid9103484-6] 6.0 ^6.1 Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J. Pharmacol. Exp. Ther. 1997, 281 (1): 93–102. PMID 9103484.

[Label-NZ-7] 7.0 ^7.1 ^7.2 存档副本 (PDF). [2019-02-17]. （原始內容 (PDF)存檔於2010-12-18）.

[Elks2014-8] J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660–. ISBN 978-1-4757-2085-3.

[IndexNominum2000-9] Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000: 716–717. ISBN 978-3-88763-075-1.

[MortonHall2012-10] I.K. Morton; Judith M. Hall. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. ISBN 978-94-011-4439-1.

[Drugs.com-11] 11.0 ^11.1 存档副本. [2019-02-17]. （原始內容存檔於2019-08-28）.

[8]

[9]

[10]

[11]

[3]

[1]

[2]

[7]

[5]

[4]

[6]